PR Newswire
4/9/2007
Copyright (C) 2007 PR Newswire. All Rights Reserved
VANCOUVER, British Columbia, April 9, 2007 /PRNewswire-FirstCall via COMTEX/ --
The following was issued today by Robert Kramer, Director, Current Technology
Corporation (OTC Bulletin Board: CRTCF):
Current Technology Corporation (the "Company") has shipped an
ElectroTrichoGenesis ("ETG") device to Tribis Inc. ("Tribis") of Seoul, Korea. A
manufacturer and distributor of cosmetic and medical devices, Tribis conducted
extensive market research and determined that in order to achieve meaningful
market penetration, full medical approval will be required. Therefore, for the
past several months, in concert with the Company, Tribis has been working with
the Korean Food and Drug Administration ("KFDA") to obtain the required
approval. Tribis believes the final step in the KFDA approval process should be
the successful conclusion of an open study (open study, as opposed to the more
complex double blind clinical trial). The Company has designed the required
protocol, and the study will be conducted by Tribis at its expense, using the
ETG provided by Current Technology. Tribis hopes to obtain full KFDA approval
early next year.
"Mr. Chou, CEO of Tribis, purchased his first unit from our former Korean
distributor, and evaluated its performance in a cosmetic setting," states
Company COO Anthony Harrison. "He is a skilled marketer, and we believe Tribis
will obtain significant market penetration once KFDA approval is in hand."
"We believe Tribis has established medical contacts which should lead to rapid
growth," states Company CEO Robert Kramer. "We look forward to working with Mr.
Chou and his team."
Current Technology Corporation remains committed to developing its non-invasive
pulsed electro-stimulation technology. This technology has enabled the Company
to develop two separate and distinct products emanating from the TrichoGenesis
platform, thus far, that offer help for those concerned with their hair:
ElectroTrichoGenesis (ETG) and CosmeticTrichoGenesis (CTG). Current Technology
holds patents throughout the world and has spent over US $15 million in research
and development of its TrichoGenesis platform and systems. The patents encompass
the technology, methodology and design of the Company's products. In addition,
the Company is seeking additional opportunities to enhance shareholder value.
The news release contains forward-looking statements concerning the Company's
business operations, and financial performance and condition. When used in the
news release the words "believe", "anticipate", "intend", "estimate", "expect",
"project", and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contains such words.
These forward-looking statements are based on current expectations and are
naturally subject to uncertainty and changes in circumstances that may cause
actual results to differ materially from those expressed or implied by such
forward-looking statements. Factors that may cause such differences include but
are not limited to technological change, regulatory change, the general health
of the economy and competitive factors. Many of these factors are beyond the
Company's control; therefore, future events may vary substantially from what the
Company's currently foresees. You should not place undue reliance on such
forward-looking statements.
SOURCE Current Technology Corporation
CONTACT: CORPORATE: Robert Kramer, of Current Technology Corporation, 1- 800-661-4247;
INVESTOR RELATIONS: Richard Hannon, Polestar Communications, 1- 866-858-4100
URL: http://www.current-technology.com
http://www.prnewswire.com
www.prnewswire.com
Copyright (C) 2007 PR Newswire. All Rights Reserved